Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 20/20 | 0.54 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24879156 | 0.96 | PTPN11 (0.53) | PTPN11MAPK3MAPK1 | |
| SCHEMBL24879245 | 0.93 | PTPN11 (0.51) | PTPN11MAPK3MAPK1 | |
| SCHEMBL27461566 | 0.92 | PTPN11 (0.46) | PTPN11MAPK3MAPK1 | |
| SCHEMBL24879187 | 0.92 | PTPN11 (0.51) | PTPN11MAPK3MAPK1 | |
| SCHEMBL24878984 | 0.92 | PTPN11 (0.48) | PTPN11MAPK3MAPK1 | |
| SCHEMBL30111002 | 0.92 | PTPN11 (0.48) | PTPN11MAPK3MAPK1 | |
| SCHEMBL24878865 | 0.92 | PTPN11 (0.55) | PTPN11MAPK3MAPK1 | |
| SCHEMBL27453103 | 0.91 | PTPN11 (0.54) | PTPN11MAPK3MAPK1 | |
| SCHEMBL24878746 | 0.90 | PTPN11 (0.53) | PTPN11MAPK3MAPK1 | |
| SCHEMBL24878881 | 0.90 | PTPN11 (0.53) | PTPN11MAPK3MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12029739-B2 | SHP2 inhibitor and use thereof | KANAPH THERAPEUTICS INC. (KR) | 2024-07-09 | — | — | US | disclosed |
| US-12029739-B2 | SHP2 inhibitor and use thereof | KANAPH THERAPEUTICS INC. (KR) | 2024-07-09 | — | — | US | disclosed |
| WO-2023282702-A1 | SHP2 INHIBITOR AND USE THEREOF | 주식회사 카나프테라퓨틱스 | 2023-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12029739-B2 | SHP2 inhibitor and use thereof | PTPN1, PTPN5, PTPN2 | PTPN11 16/4885MAPK3 389/4885MAPK1 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.